Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and welcome to the Nanobiotics Business Update and Full Year 2024 Financial Results Conference call. At this time, all participants are in a listen-only mode. After the speakers' presentations, there will be a question and answer session. Please be advised that today's conference is being recorded. At this point, I would turn the call over to Greg West, Senior Vice President of Investor Relations of Nanobiotics. Please go ahead. Thank you. Good afternoon and good morning, and welcome to the Nanobiotics Conference call to discuss our full year 2024 financial and operational results. Joining me on the call today are Laurent Levy, co-founder and chief executive officer, and Bart Van Ryn, chief financial and business officer. As a reminder, today's call is being webcast and will be available on our website for replay. On the next slide, slide two, I would like to remind you that this call will include forward-looking statements, which may include statements regarding the progress, success, and timing of our ongoing and planned clinical trials, collaborations, regulatory filings, dates of presentation, and future research and development efforts, amongst other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. They are subject to significant risks and uncertainties that could cause the company's actual results to differ materially from our current expectations. Accordingly, you are cautioned not to place undue reliance on forward-looking statements. Please review the full description of risk factors that can be found in the documents we filed with the AMF in France and SEC in the United States, which are available in the Investor Relations section of our website, along with the pres...